Compare MIRM & FICO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | FICO |
|---|---|---|
| Founded | 2018 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 34.7B |
| IPO Year | 2019 | 1995 |
| Metric | MIRM | FICO |
|---|---|---|
| Price | $101.26 | $1,250.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | $119.85 | ★ $1,689.92 |
| AVG Volume (30 Days) | ★ 1.0M | 329.4K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | 29.78 |
| EPS | N/A | ★ 17.73 |
| Revenue | $19,138,000.00 | ★ $1,032,475,000.00 |
| Revenue This Year | $26.22 | $27.28 |
| Revenue Next Year | $22.04 | $16.97 |
| P/E Ratio | ★ N/A | $72.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.50 | $870.01 |
| 52 Week High | $114.99 | $1,998.01 |
| Indicator | MIRM | FICO |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 66.95 |
| Support Level | $95.68 | $1,193.10 |
| Resistance Level | $107.51 | $1,593.96 |
| Average True Range (ATR) | 5.22 | 53.98 |
| MACD | -0.65 | 17.34 |
| Stochastic Oscillator | 33.42 | 77.87 |
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.